BiotechTube

Dupilumab

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Atopic Dermatitis

Conditions

Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions

Trial Timeline

Oct 22, 2018 → Feb 23, 2023

NCT ID
NCT03293030

About Dupilumab

Dupilumab is a approved stage product being developed by Sanofi for Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03293030. Target conditions include Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (20)

NCT IDPhaseStatus
NCT05906706Pre-clinicalCompleted
NCT07316114Pre-clinicalRecruiting
NCT07467564Pre-clinicalRecruiting
NCT07187089ApprovedWithdrawn
NCT07112378Phase 3Recruiting
NCT07052396Pre-clinicalRecruiting
NCT07276425Pre-clinicalRecruiting
NCT06695897Pre-clinicalRecruiting
NCT06693531Pre-clinicalRecruiting
NCT06415175Pre-clinicalActive
NCT06556264ApprovedRecruiting
NCT06352073ApprovedRecruiting
NCT06293053Phase 3Recruiting
NCT05983068ApprovedActive
NCT06234761Pre-clinicalRecruiting
NCT05991323Pre-clinicalActive
NCT06192563Pre-clinicalRecruiting
NCT06169527Pre-clinicalActive
NCT06393946Pre-clinicalActive
NCT05831176Phase 2Active

Competing Products

20 competing products in Atopic Dermatitis

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
YH35324 + Placebo + OmalizumabYuhanPhase 1
33
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84
alglucosidase alfaApproved
84